Guillermo Garcia-Manero, MD - The Future is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management
Go online to PeerView.com/PMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It’s a new era for treatment of myelodysplastic syndrome (MDS), one where clinicians increasingly have an opportunity to customize care for every patient according to risk factors and other baseline features. Are you prepared for the tailored use of erythroid maturation agents, fixed-dose combinations, newer targeted agents, and novel immune-based strategies? Find out by viewing this activity, based on a recent live symposium, where leading experts examine the connection between the latest evidence and the real-world practice of personalized, risk-adapted MDS management. During this program, you’ll see how foundational lectures link directly to "Case Forum" discussions that explore baseline prognostic assessment and the integration of novel therapeutics into the management of lower- and higher-risk disease. Don’t miss this engaging and case-centered activity! Upon completion of this activity, participants should be better able to: Describe the patient- and disease-related features, including age and molecular/cytogenetic features along with risk assessment, that influence prognosis and guide treatment decisions for MDS; Summarize the updated clinical efficacy and safety evidence on currently approved and emerging treatments for newly diagnosed or relapsed/refractory MDS; Incorporate novel and emerging therapies into treatment plans across a range of disease settings based on current clinical evidence and patient and disease features; and Develop strategies to address the unique spectrum of adverse events associated with novel and emerging therapies for MDS.